adam15 overexpression sequence Search Results


adam15 overexpression sequence  (Genechem)
90
Genechem adam15 overexpression sequence
Primer sequences.
Adam15 Overexpression Sequence, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adam15 overexpression sequence/product/Genechem
Average 90 stars, based on 1 article reviews
adam15 overexpression sequence - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Primer sequences.

Journal: CytoJournal

Article Title: A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1

doi: 10.25259/Cytojournal_92_2024

Figure Lengend Snippet: Primer sequences.

Article Snippet: The ADAM15 overexpression sequence was synthesized by GeneChem (China, Shanghai).

Techniques: Sequencing

Impacts of ADAM15 overexpression on tumor migration, invasion, and proliferation. (a and b) Measurement of ADAM15 protein expression. (c) Measurement of ADAM15 mRNA expression. (d) Evaluation by scratch assay, Scale bar = 100 μm. Objective: 100×. (e) Relative migration rate in U251 and U87 for scratch assay. (f) Evaluation of U251 and U87 migration for 12 h through transwell assay, Scale bar = 50 μm. Objective: 200×. (g) Migrated cells per field in U251 and U87 for the transwell assay. (h) Evaluation of transwell assay, with Matrigel in U251 and U87 invasion for 72 h. Scale bar = 50 μm. Objective: 200×. (i) Relative invasion rate in U251 and U87 for the transwell assay. n = 5 independent replicates. ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15, mRNA: Messenger RNA.

Journal: CytoJournal

Article Title: A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1

doi: 10.25259/Cytojournal_92_2024

Figure Lengend Snippet: Impacts of ADAM15 overexpression on tumor migration, invasion, and proliferation. (a and b) Measurement of ADAM15 protein expression. (c) Measurement of ADAM15 mRNA expression. (d) Evaluation by scratch assay, Scale bar = 100 μm. Objective: 100×. (e) Relative migration rate in U251 and U87 for scratch assay. (f) Evaluation of U251 and U87 migration for 12 h through transwell assay, Scale bar = 50 μm. Objective: 200×. (g) Migrated cells per field in U251 and U87 for the transwell assay. (h) Evaluation of transwell assay, with Matrigel in U251 and U87 invasion for 72 h. Scale bar = 50 μm. Objective: 200×. (i) Relative invasion rate in U251 and U87 for the transwell assay. n = 5 independent replicates. ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15, mRNA: Messenger RNA.

Article Snippet: The ADAM15 overexpression sequence was synthesized by GeneChem (China, Shanghai).

Techniques: Over Expression, Migration, Expressing, Wound Healing Assay, Transwell Assay

Impact of ADAM15 overexpression on the proliferation ability of glioblastoma cells. (a) Measurement of colony number in U251 and U87. (b) Clonogenic assay in U251 and U87. (c) EdU incorporation in U251 and U87. Scale bar = 20 μm. Objective: 400×. (d) Proliferation rates in U251 and U87 for EdU incorporation. (e) Evaluation of Ki67 immunohistochemistry staining. Scale bar = 20 μm. Objective: 400×. (f) Ki67 positive cell rates in U251 and U87 for Ki67 immunohistochemistry staining. n = 5 independent replicates. ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15.

Journal: CytoJournal

Article Title: A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1

doi: 10.25259/Cytojournal_92_2024

Figure Lengend Snippet: Impact of ADAM15 overexpression on the proliferation ability of glioblastoma cells. (a) Measurement of colony number in U251 and U87. (b) Clonogenic assay in U251 and U87. (c) EdU incorporation in U251 and U87. Scale bar = 20 μm. Objective: 400×. (d) Proliferation rates in U251 and U87 for EdU incorporation. (e) Evaluation of Ki67 immunohistochemistry staining. Scale bar = 20 μm. Objective: 400×. (f) Ki67 positive cell rates in U251 and U87 for Ki67 immunohistochemistry staining. n = 5 independent replicates. ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15.

Article Snippet: The ADAM15 overexpression sequence was synthesized by GeneChem (China, Shanghai).

Techniques: Over Expression, Clonogenic Assay, Immunohistochemistry, Staining

Impacts of ADAM15 overexpression on PAR1 expression and EMT. (a and b) Measurement of PAR1 protein expression in U251 and U87. (c) Measurement of PAR1 mRNA expression in U251 and U87. (d) Measurement of E-cadherin, N-cadherin, and Vimentin protein expression in U251 and U87. (e) Relative E-cadherin protein expression in U251 and U87. (f) Relative N-cadherin protein expression in U251 and U87. (g) Relative Vimentin protein expression in U251 and U87. (h) Immunofluorescence of E-cadherin and Vimentin staining in U251 and U87. Scale bar = 20 μm. Objective: 400×. n = 5 independent replicates. ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15, PAR1: Protease-activated receptor 1, Epithelial-mesenchymal transition, mRNA: Messenger RNA.

Journal: CytoJournal

Article Title: A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1

doi: 10.25259/Cytojournal_92_2024

Figure Lengend Snippet: Impacts of ADAM15 overexpression on PAR1 expression and EMT. (a and b) Measurement of PAR1 protein expression in U251 and U87. (c) Measurement of PAR1 mRNA expression in U251 and U87. (d) Measurement of E-cadherin, N-cadherin, and Vimentin protein expression in U251 and U87. (e) Relative E-cadherin protein expression in U251 and U87. (f) Relative N-cadherin protein expression in U251 and U87. (g) Relative Vimentin protein expression in U251 and U87. (h) Immunofluorescence of E-cadherin and Vimentin staining in U251 and U87. Scale bar = 20 μm. Objective: 400×. n = 5 independent replicates. ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15, PAR1: Protease-activated receptor 1, Epithelial-mesenchymal transition, mRNA: Messenger RNA.

Article Snippet: The ADAM15 overexpression sequence was synthesized by GeneChem (China, Shanghai).

Techniques: Over Expression, Expressing, Immunofluorescence, Staining

Inhibition of ADAM15-induced proliferation, migration, and invasion by PAR-1 antagonist treatment. (a) Evaluation by scratch assay after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. Scale bar = 100 μm. Objective: 100×. (b) Relative migration rate for scratch assay after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. (c) Evaluation by transwell assay with Matrigel invasion for 72 h. Scale bar = 50 μm. Objective: 200×. (d) Relative invasion rate for transwell assay after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. (e) Clonogenic assay in U251 and U87. (f) Measurement of colony number after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. n = 5 independent replicates. ns: No significant, ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15, PAR1: Protease-activated receptor 1.

Journal: CytoJournal

Article Title: A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1

doi: 10.25259/Cytojournal_92_2024

Figure Lengend Snippet: Inhibition of ADAM15-induced proliferation, migration, and invasion by PAR-1 antagonist treatment. (a) Evaluation by scratch assay after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. Scale bar = 100 μm. Objective: 100×. (b) Relative migration rate for scratch assay after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. (c) Evaluation by transwell assay with Matrigel invasion for 72 h. Scale bar = 50 μm. Objective: 200×. (d) Relative invasion rate for transwell assay after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. (e) Clonogenic assay in U251 and U87. (f) Measurement of colony number after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment. n = 5 independent replicates. ns: No significant, ✶ ✶ ✶ P < 0.001. ADAM15: A disintegrin-like and metalloproteinase 15, PAR1: Protease-activated receptor 1.

Article Snippet: The ADAM15 overexpression sequence was synthesized by GeneChem (China, Shanghai).

Techniques: Inhibition, Migration, Wound Healing Assay, Transwell Assay, Clonogenic Assay

Inhibition of ADAM15-induced EMT by PAR-1 antagonist treatment. (a) Western blotting of E-cadherin, N-cadherin, and Vimentin protein expression after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment in U251. (b) Histogram of E-cadherin, N-cadherin, and Vimentin protein expression in U251. (c) Western blotting of E-cadherin, N-cadherin, and Vimentin protein expression after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment in U87. (d) Histogram of E-cadherin, N-cadherin, and Vimentin protein expression in U87. (e) Immunofluorescence of E-cadherin and Vimentin staining in U251 and U87. Scale bar = 20 μm. Objective: 400×. n = 5 independent replicates. ns: Not significant, ✶ ✶ P < 0.01. ADAM15: A disintegrin-like and metalloproteinase 15, PAR1: Protease-activated receptor 1, Epithelial-mesenchymal transition.

Journal: CytoJournal

Article Title: A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1

doi: 10.25259/Cytojournal_92_2024

Figure Lengend Snippet: Inhibition of ADAM15-induced EMT by PAR-1 antagonist treatment. (a) Western blotting of E-cadherin, N-cadherin, and Vimentin protein expression after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment in U251. (b) Histogram of E-cadherin, N-cadherin, and Vimentin protein expression in U251. (c) Western blotting of E-cadherin, N-cadherin, and Vimentin protein expression after PAR-1 antagonist SCH79797 or PAR-2 antagonist FSLLRY-NH2 treatment in U87. (d) Histogram of E-cadherin, N-cadherin, and Vimentin protein expression in U87. (e) Immunofluorescence of E-cadherin and Vimentin staining in U251 and U87. Scale bar = 20 μm. Objective: 400×. n = 5 independent replicates. ns: Not significant, ✶ ✶ P < 0.01. ADAM15: A disintegrin-like and metalloproteinase 15, PAR1: Protease-activated receptor 1, Epithelial-mesenchymal transition.

Article Snippet: The ADAM15 overexpression sequence was synthesized by GeneChem (China, Shanghai).

Techniques: Inhibition, Western Blot, Expressing, Immunofluorescence, Staining